Relationship of subcellular expression of GS28 with clinicopathological features of cervical cancer tissues.

<p>Relationship of subcellular expression of GS28 with clinicopathological features of cervical cancer tissues.</p

Immunoblotting of cervical cancer tissue extracts.

<p>Whole (W), cytoplasmic (C), and nuclear (N) fractions were prepared from tissues of one adenocarcinoma (ADC) and five squamous cell carcinomas (SqCC), and GS28 expression in the fractions was examined by immunoblotting using the anti-GS28 antibody. Laminin B1 and α-tubulin were used as the nuclear and cytoplasmic markers, respectively.</p

Relationship of nuclear expression of GS28 with p53 and Bcl-2 expression in cervical cancer tissues.

<p>Relationship of nuclear expression of GS28 with p53 and Bcl-2 expression in cervical cancer tissues.</p

Multivariate Cox regression analysis for overall survival and progression-free survival in negative-lymph node-metastasis subgroup (N = 132) of cervical cancer patients.

<p>Multivariate Cox regression analysis for overall survival and progression-free survival in negative-lymph node-metastasis subgroup (N = 132) of cervical cancer patients.</p

Multivariate Cox regression analysis for overall survival and progression-free survival in cervical cancer patients (N = 177).

<p>Multivariate Cox regression analysis for overall survival and progression-free survival in cervical cancer patients (N = 177).</p

Kaplan-Meier curves of univariate analysis data (log-rank test).

<p>(A) The overall survival (OS) and (B) progression-free survival (PFS) of cervical cancer patients with high versus low nuclear expression of GS28. (C) The OS and (D) PFS of patients with stage T1 tumors (pT1 subgroup), and (E) the OS and (F) PFS of patients without lymph node metastasis (negative-lymph node-metastasis subgroup) with high versus low nuclear expression of GS28.</p